NASDAQ:BCRX

Biocryst Pharmaceuticals Stock News

etoro logo Buy BCRX
*Your capital is at risk
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
RESEARCH TRIANGLE PARK, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2020 financial results on
SG Americas Securities LLC grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1,399.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC
BioCryst's position has improved on several fronts in the last few months. The company raised cash, reported preliminary positive results of BCX9930 in PNH patients, and there is now upside optionalit
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
North Star Investment Management Corp. acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the
BioCryst’s moonshot probably won’t be as good for shareholders as Moderna’s has already been.

Antivirals In The COVID-19 Space

06:33pm, Monday, 13'th Jul 2020
A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.
Brokerages expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post $3.17 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Bio

6 Stocks That Could Pop Higher

12:00am, Wednesday, 08'th Jul 2020
Stocks Analysis by Harry Boxer covering: BioCryst Pharmaceuticals Inc, Cytokinetics Inc, Vaxart Inc, Novavax Inc. Read Harry Boxer's latest article on Investing.com
There might be a simple explanation for why the company doubled the expected enrollment in its COVID-19 clinical trial.
If you want to know who really controls BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), then you'll have to look at the...
Is (BCRX) Outperforming Other Medical Stocks This Year?
The likelihood appears slim of an adequately effective and widely available vaccine being in commercial use before H2 2021.
Legal & General Group Plc lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 6.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an a
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE